Details of the Drug Combination

General Information of Drug Combination (ID: DC3EEIP)

• Drug Combination Name: IT-141 + Diethylcarbamazine
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  IT-141 (DMAYD7O): N.A.
  Diethylcarbamazine (DM1TJ8F): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 0.76
  Bliss Independence Score: 0.76
  Loewe Additivity Score: 1.83
  LHighest Single Agent (HSA) Score: 1.89

Molecular Interaction Atlas of This Drug Combination

Indication(s) of IT-141

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

IT-141 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[2]

Indication(s) of Diethylcarbamazine

Disease Entry	ICD 11	Status	REF
Elephantiasis	N.A.	Approved	[3]
Loiasis	N.A.	Approved	[3]
Lymphatic filariasis	1F66.3	Approved	[4]
Onchocerciasis	1F6A	Approved	[3]

Diethylcarbamazine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Inhibitor	[5]

Diethylcarbamazine Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases Activity	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Diethylcarbamazine FDA Label
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [6] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.